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Transforming growth factor (TGF) β is known to have properties of both a tumour
suppressor and a tumour promoter. While it inhibits cell proliferation, it also increases cell
motility and decreases cell-cell adhesion. Coupling mathematical modeling and experiments,
we investigate the growth and motility of oncogene-expressing human mammary epithelial
cells under exposure to TGF–β. We use a version of the well-known Fisher–Kolmogorov
equation, and prescribe a procedure for its parametrisation. We quantify the simultaneous
effects of TGF–β to increase the tendency of individual cells and cell clusters to move
randomly and to decrease overall population growth. We demonstrate that in experiments
with TGF–β treated cells in vitro, TGF–β increases cell motility by a factor of 2 and
decreases cell proliferation by a factor of 1/2 in comparison with untreated cells.
Keywords: Transforming growth factor (TGF) β, cell growth and motility, mathematical
model, Fisher–Kolmogorov equation
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1. Introduction to the Biology of TGF–β
In normal organisms, the growth of cells is under tight regulation by growth fac-
tors and is highly dependent on the developmental stage during the lifespan of the
organism. Disruption of this regulation is the most frequent cause of cancer dis-
eases. Unlike normal differentiated cells, cancer cells are usually hyperproliferative
as a result of the abnormal activation of multiple growth–stimulating intracellular
signalling pathways and loss of tumour suppressors. In cancer cells, these pathways
do not respond to normal regulatory signals but are manipulated by one or more
oncogenic signals, often encoded by oncogenes. Expression of oncogenes alters sig-
nalling pathways that under normal conditions maintain cell growth homeostasis.
Thus, altering these pathways may favour increased cell and cancer growth. A good
example is the transforming growth factor (TGF) β family, which is known to be
able to act as both a tumour suppressor and tumour promoting factor.
The TGF–β family consists of multitasking cytokines that play important roles
in cell proliferation, cell motility, apoptosis, lineage determination, extracellu-
lar matrix production, and modulation of immune function [22]. These ligands
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bind to a heteromeric complex of transmembrane serine/threonine kinases, the
type I and type II receptors (TβRI and TβRII). The receptors are activated
upon ligand binding, leading to the subsequent phosphorylation and activation
of a family of transcription factors called Smads, which regulate transcription
of a subset of genes [23]. In addition to Smads, other signalling pathways have
been implicated in TGF–β actions in recent studies. These include the extracel-
lular signal–regulated kinase (ERK, MAPK), c–Jun NH2–terminal kinase (JNK),
p38MAPK, phosphatidylinositol–3 kinase (PI3K), and Rho GTPases (reviewed in
[7, 11, 39, 43]). The critical role of these non–Smad pathways on mediating the
cellular effects of TGF–β remains to be fully characterised.
TGF–β was originally reported to induce transformation of mouse fibroblasts
[24]. Subsequent studies indicated that TGF–β is a potent inhibitor of cell pro-
liferation and a tumour suppressor [32, 36]. Consistent with its tumour suppres-
sor role, many cancers lose or attenuate TGF–β–mediated anti–mitogenic action
by mutational inactivation of TGF–β receptors or their signal transducer Smads
[13, 15, 16, 20, 40, 41]. There is increasing evidence to show that excess production
and/or activation of TGF–β in tumours can accelerate cancer progression through
enhancement of tumour cell motility and survival, increase in tumour angiogenesis,
extracellular matrix production and peritumoural proteases, and the inhibition of
immune surveillance mechanisms in the cancer host (reviewed in [7, 9, 11]). Cancer
progression and metastasis consist of a series of sequential events. After initial cell
transformation, often mediated by the function of oncogenes, tumour cells grow-
ing at the primary site will invade the surrounding stroma and migrate towards
blood vessels. Through various mechanisms such as epithelial–mesenchymal tran-
sition (EMT), tumour cells will enter the blood vessels and travel to other parts
of the body through the circulatory system. Some of the cells will then arrest at
distant sites where they may proliferate and invade into the adjacent organs. Cell
motility is therefore a critical element during the spread of tumour cells from their
initial sites of residence. In this study, we focus on the tumour–promoting effect of
TGF–β through inducing cell motility.
The receptor tyrosine kinase HER2 (ErbB2, Neu) belongs to the family of epi-
dermal growth factor receptor (EGFR). Gene amplification or overexpression of
HER2 is observed in about 25% of breast cancers. TGF–β has been shown to
synergize with the oncogene ErbB2 in cancer progression. Overexpression of ac-
tive TGF–β 1 or active mutants TβRI (Alk5) in the mammary gland of bigenic
mice also expressing mouse mammary tumour virus (MMTV)/Neu (ErbB2) accel-
erates metastases from Neu–induced mammary cancers [25, 26, 27, 35]. Exogenous
as well as transduced TGF–β confer motility and invasiveness to MCF10A non–
transformed human mammary epithelial cells (HMEC) stably expressing trans-
fected HER2 [34, 38]. Expression of the oncogene HER2 in these cells does not
affect the function of TGF–β on inhibiting cell proliferation [38]. It is likely that
in many cancers, TGF–β may still attenuate proliferation while inducing cellular
events associated with metastatic dissemination, such as cell motility. In this paper
we report experiments with MCF10A/HER2 cells to study and to separate the ef-
fects of TGF–β on cell proliferation and motility. Due to the complexity of TGF–β
signalling that simultaneously affects several biological parameters, it is important
to computationally simulate the behaviour of cells under TGF–β exposure. Our
model, which can also be adopted to simulate other growth–regulating signals, will
provide a unique insight into the TGF–β function in both normal and cancer cells,
and further understanding of targeted therapeutic strategies that aim at interfering
with TGF–β signalling.
Mathematical modeling of chemotherapy with Tamoxifen has been carried out
November 17, 2018 11:41 Computational and Mathematical Methods in Medicine TGF-
beta˙May˙1
A mathematical model quantifies proliferation and motility effects of TGF–β on cancer cells 3
in [37], with special consideration of TGF–β. There, the authors use a discrete
cellular automaton (CA) model to investigate the effects of TGF–β on tumour
morphology and invasiveness. It is possible to assign properties to individual cells
in a cellular automaton model (such as different levels of malignancy). However,
they can be computationally costly, in particular in situations where large cell
populations are involved. Since we are interested chiefly in the effects of TGF–β on
a large number of cells growing in a plate, rather than individual cell behaviour,
we work with a continuous partial differential equation model. Future research
problems may require the construction of hybrid models such as in [1] where discrete
cells are coupled to continuous fields that in turn are solutions of partial differential
equations.
2. Introduction to the Mathematical Model
The Fisher–Kolmogorov equation (or KPP equation) has been studied and used
widely in mathematical biology. It originated in the 1930s in works of R. A. Fisher
and A. N. Kolmogorov [12, 18] where it was proposed as a model for the spread of
an advantageous gene in a population. Mathematically, it falls into the large class
of reaction–diffusion equations, in which one or more diffusible “species” enter
into a scheme of reactions. The species can be chemical substances or biological
populations. Reaction–diffusion equations in general and the Fisher–Kolmogorov
equation in particular have been applied successfully by many authors to model
the behaviour of cells in tissues, see for example [1, 2, 5, 6, 8, 10, 19, 30]. The
Fisher–Kolmogorov equation is usually used to show traveling wave behaviour, but
we use it here to model the spatial growth of a cell culture from initial seeding to
confluence.
Let u(x, y, t) denote the spatial density of tumour cells at time t in a dish corre-
sponding to a spatial region Ω ⊂ R2. The time evolution of this density is described
by the partial differential equation
∂
∂t
u(x, y, t) = D∆u(x, y, t) + αu(x, y, t)(1− βu(x, y, t)). (1)
Here α incorporates the intrinsic proliferation rate (unit time−1), from initial seed-
ing to confluence, in a single value independent of x, y, t. Also, β denotes the area
occupied by an average single cell. The density satisfies, u(x, y, t) ≤ β−1 for all
x, y, t, and the total number of cells in the region Ω ⊂ R2 at time t is given by
N(t) =
∫ ∫
Ω
u(x, y, t) dx dy.
The spatial region Ω may be the entire region occupied by the population or a
subfield thereof. Equation (1) is accompanied by an initial condition and appro-
priate boundary conditions. If a subfield Ω1 of Ω is completely populated, then
u(x, y, t) = β−1 for all x, y ∈ Ω1, otherwise u(x, y, t) ≤ β−1 and
β
|Ω1|
∫ ∫
Ω1
u(x, y, t) dx dy
is the fraction of possible cells in Ω1 at time t. Here and in the sequel | · | denotes
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the area of the domain in question. We denote the total mass of the density by
U(t) = β
∫ ∫
Ω
u(x, y, t) dx dy. (2)
Much of the remainder of this paper will be concerned with the problem of finding
parameter values to a modified version of equation (1) from experimental observa-
tions and with the interpretation of the solution to the equation.
The diffusion constant D in equation (1) has to account for three simultaneous
processes contributing to the spatial movement of cells. First, dividing cells occupy
increasing space, therefore a certain part of D, say Dp, has to account for the
spatial expansion of proliferating cells. The authors of [6, 8, 19, 30] have proposed
relations of the type
Dp = k1
`2
Td
.
Here ` is related to the typical length or diameter of a cell and Td is the doubling
time. The dimensionless factor k1 in [8] accounts for the expansion of the viable
rim of dividing cells. We take ` to be the average increase in cell diameter between
mitotic events. We assume the area of an average cell increases from approximately
50µm2 to 100µm2, so we take ` = 3.3µm. We assume the average cycle time is
Td = 16h. We take Dp = 0.1µm2h−1 (order of magnitude). Second, individual cells
plated on a Petri dish do not remain fixed in their position but undergo a random
walk. It is natural to assume that the random walk is not biased and follows the
laws of Brownian motion. Third, cells in a cluster may break lose from that cluster
as TGF–β is known to decrease cell–cell adhesion [28]. Thus, a part of D, say Dm,
must account for this second and third contribution to cell movement.
We propose here a modification of the standard Fisher–Kolmogorov equation
(1). Our reasoning is that as the cells become more densely packed, their random
motility should decrease. Thus, with U from equation (2) we propose
∂
∂t
u(x, y, t) = ∇ · (D(U)∇u(x, y, t)) + αu(x, y, t)(1− βu(x, y, t)),
D(U) = Dm
(
1− U|Ω|
)
+Dp.
(3)
The constant Dm, which captures the random motility of individual cells and clus-
ters and the tendency of clusters to break apart, depends on TGF–β concentration.
We remark here that D could also be made dependent on the local density u. In
the case of interest to us in the present paper the initial seeding of the cells results
in a uniform dispersion of the population that justifies the approximation made
in equation (3). Since Dp > 0, D(U) > 0 and the modified equation (3) has the
important property of mathematical well–posedness. In practical applications, Dp
is often considerably smaller than Dm (see the Results section and table 2 for our
numerical parameter values).
Different numerical values for the constant Dm have been proposed in the liter-
ature. Bray reports in his 1992 book [4, Table 1–1] Dm = 5 · 10−10 cm2 s−1 =
180µm2h−1. Chaplain and Matzavinos [6] arrive at a similar value Dm = 7 ·
10−5 cm2 day−1 = 300µm2h−1. This value is obtained in [6] from the Einstein–
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Stokes equation [3]
D =
kBT
3pidη
,
where kB is Boltzmann’s constant, T the temperature, d the diameter of the cells,
and η the dynamic viscosity of the surrounding medium. It can be excluded, how-
ever, that cells in vitro, such as in our experiments, move in an environment that
has the viscosity of water, ηH2O = 10−3 Pa s. Thermally driven motion and Stokes
friction are not relevant in the context of moving cells.
3. Materials and Methods
MCF10A/HER2 cells were generated and grown as described [38]. All live cell
imaging experiments were performed in triplicate. For growth assay, equal number
of cells (1.5 · 104/well) suspended in full medium were seeded on 6–well plates.
Cells were allowed to grow in the absence or presence of TGF–β at different con-
centrations (0.5 − 5ngml−1) over a time course of 8 days. Medium containing
fresh TGF–β was replenished every 2 days. Cells were harvested by trypsinization
every 24h, and subjected to total cell number counting using a Coulter counter.
In Figure 4 B each data point represents the mean of 3 wells. Standard deviations
were less than 5% in all cases and were not included in the figure. For random
motility assay of individual cells, cells were seeded on 6–well plates at 3 · 104/well
one day prior to image recording. For motility of cell clusters, cells were seeded
at 104/well two days prior to image recording. Culture media was replaced with
fresh serum–free or full L–15 medium and different concentrations of TGF–β was
added 1h before the image recording. Cells were imaged on a Nikon TE 2000–E
microscope and captured using a Hamamatsu Orca ER camera and Metamorph
software. Images were taken every 5 minutes for 270 minutes for random motility
assays and every 30 minutes for 14 hours for the cell cluster experiments. Image
analysis was performed using Metamorph software (MDS, Inc., Toronto, Canada).
4. Results
4.1. Random motility of individual cells
We have taken position measurements of individual cells and have obtained time
series data (xi, yi)Ni=1, with ∆T = 5min. The mean–squared displacement (MSD)
is calculated according to
r2(k∆T ) =
1
N − k
N−k∑
i=1
(
(xi+k − xi)2 + (yi+k − yi)2
)
, (4)
where k = 1, 2, . . . , kmax. The maximal multiple kmax for which r2 is calculated
has to be chosen carefully. Obviously, the bigger k, the fewer such displacements
are contained in the time series of length N thus the larger the uncertainty in the
estimate r2(k). The paper [31] gives estimates of the standard deviation of r2(k)
in terms of N and kmax. To obtain the random motility of a single cell we fit the
estimate (4) with a linear function (see [3] for a discussion of this relation)
r2(k∆T ) = 4Dmk∆T. (5)
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Unfortunately, the analysis is made difficult by cells that seem to remain immobile
or whose r2(k)–curves do not look linear. For the plots in Figure 1 we have selected
only curves that could be fit reasonably by a straight line. Other curves show cells
moving initially and then coming to a standstill. Moreover, we cannot see a clear
increase of Dm as TGF–β is added. For the average random motility of individual
isolated mobile cells we obtain, both for cells treated with 0 and with 5ngml−1
TGF–β,
Dm = 120µm2h−1.
This value can be taken as an upper bound which is realised only if all cells are
mobile.
We now look at the percentage of mobile cells. We define a cell to be mobile if it
moves outside of a 100µm× 100µm square centred at the cell’s original position.
It becomes clear (Table 1) that the percentage of mobile cells in our experiment
increases as TGF–β is introduced.
It seems to be a frequently observed phenomenon that a certain subpopulation of
cells remains immobile. Selmeczi et al. [33] observed different types of keratinocytes
and fibroblasts and selected trajectories only for cells that were moving at all. This
selection procedure is clearly admissible for single particle tracking experiments,
but is not applicable to a population with a high fraction of non–mobile cells. We
want to emphasize that the cells are not subject to a directional gradient of TGF–
β, rather a uniform concentration applied from all directions, therefore they are
able to move randomly in any direction, as opposed to being stimulated to move in
one particular direction. Although it is unknown why cells suddenly stop moving,
it is possible that in the absence of a strong directional signal there is “noise” in
the motility signaling that leads to immotility in randomly moving cells.
4.2. Random motility of cell clusters
We next investigated the motility of cell clusters (≈ 10 cells) in the absence or
presence of TGF–β. As shown in Figure 2, top row, untreated cell clusters are
relatively immobile and seem to maintain a certain shape, although the cells can
still rotate within the clusters. In contrast, clusters treated with TGF–β are sig-
nificantly more active in altering their shape and migrating towards unoccupied
space (Figure 2, bottom row). We analysed the movie data in the following way.
On the initial frame of the movie the centre of the cluster is identified as the centre
of the smallest rectangle containing the cluster. Then, on each subsequent frame of
the movie, a straight line is drawn to the point on the boundary of the cluster the
farthest from the initial centre. The time gap between two frames is ∆T = 1h. We
obtain a star of radii as shown in Figure 3 A. For a time series of N radii (ri)Ni=1
we calculate the variation of the squares
v2 =
1
N − 1
N−1∑
i=1
|r2i+1 − r2i |. (6)
For a total of 36 movies, 18 control cases and 18 treatment cases (5 or 10ngml−1)
respectively, a difference can be seen in the value of the variation v2 (Figure 3 B)
with TGF–β treated cells showing a higher value than untreated cells. Movies were
obtained both under serum–free conditions and with serum. The clusters treated
with TGF–β are more active by a factor of two.
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We combined the observations of individual mobile cells and clusters of cells to
obtain values of Dm = 5µm2h−1 (TGF–β concentration 0) and Dm = 10µm2h−1
(TGF–β concentration 5ngml−1). These values are scaled downwards from the
upper bound obtained from the single cell motility experiments in view of the fact
that only a fraction of cells are fully mobile. The ratio of the Dm’s for treated and
untreated case is suggested by our experimental observations.
4.3. Growth assays and their numerical simulation
The mathematical model from equation (3) was programmed using matlab (ver-
sion 7.1, The MathWorks, Inc., Natick, MA). A standard Crank–Nicolson scheme
is used for the diffusion step [29, Section 17.3], combined with an Euler forward
reaction step. The codes will be available upon request from the corresponding
author.
We fix the following length and time scales for our simulations. The square
domain has side length L = 300µm and the time unit is T = 1h. We assume
that a single cell occupies an area of β = 100µm2, thus the field has a carrying
capacity of 900 cells. We impose periodic boundary conditions to account for the
fact that our numerical domain is a small section of a larger domain, say a Petri
dish. Thus, a cell mass that leaves the region will be balanced by a cell coming in
at the opposite side. It should also be pointed out that the carrying capacity is the
same in control and treatment cases.
Numerical simulations of cells growing in a field are shown in Figure 4 A. The
initial datum resembles the random placement of cells on the Petri dish. Using
our modified Fisher–Kolmogorov equation (3) we can simulate the experimentally
determined growth data (Figure 4 B, discrete symbol represent experimental data,
continuous curves represent simulations). At first, the experimental growth data
were normalised with respect to a maximum capacity of 1.1 ·105 cells. The parame-
ter α was obtained from fitting the experimental data (see Fig. 4 B), while Dm and
Dp were chosen as stated above. The numerical simulation starts only 72h into the
experiment. In our previous experiments with these cells [17], we have noticed that
after the cells suspended in medium are seeded onto the plates, they require about
48 hours to adhere to and spread on the plates and adjust to their new environ-
ment, before they start a typical growth regime. The numerical parameter values
are collected in table 2. To support our choice of α we note that if the cells were
able to grow exponentially according to the law u′ = αu, then the corresponding
doubling times T2 = ln 2/α would be T−2 = 10h for untreated cells (α = 0.07h
−1)
and T+2 = 17h for cells treated with TGF–β (α = 0.04h
−1). These doubling times
are feasible for MCF10A/HER2 cells in the early exponential growth phase.
5. Discussion and Conclusions
Our experiments demonstrate that TGF–β increases the percentage of mobile cells
in a cell population in a dose–dependent manner, rather than increases the mean
square migration displacement of individual cells. As we demonstrated, random mi-
gration of cell clusters containing ≈ 10 cells is a feasible approach to parametrise
the unbiased random cell migration in a large population of cells. The cluster
motility assay indicates that clusters are more mobile and/or less cohesive if TGF–
β is present. In fact, biological evidence for both mechanisms has been identified.
TGF–β induces a PI3K–mediated activation of Rac1/Pak1 pathway, which leads
to increased cytoskeleton reorganisation, turnover of focal adhesion, and eventu-
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ally cell migration [42]. Furthermore, TGF–β downregulates cell–cell adhesion by
decreasing the adhesion protein E–cadherin [28]. The cluster motility assay reflects
an overall effect of the multifunctional molecule TGF–β on motility. In metastatic
cancer cells, TGF–β stimulates epithelial–mesenchymal transition (EMT) which
is necessary for the acquisition of invasive and metastatic phenotype. It has been
shown that in cell monolayer wounded with a pipette tip, the presence of TGF–β
in the medium markedly induces the closure of wounded area, which is another
indicator of TGF–β–induced cell motility. However, this assay is not used in our
parametrisation as the cell migration is not random but targeted to the wounded
area.
Our model has a relatively small number of parameters: Dp, β, Dm, and α.
Our procedure for determining these parameters is as follows: (1) Dp and β are
determined by the average doubling time and average area of cells in the culture, re-
spectively. (2) Dm is determined by adjusting the motility measurements of isolated
mobile cells and clusters of mobile cells for their fraction of the total population as
the culture attains confluence. From our experiments the upper estimate on Dm
was 120µm2h−1, which we adjusted downward by ≈ 1 order of magnitude to com-
pensate for the fraction of mobile cells in the total population. Table 1 provides the
fractions of mobile cells for varied concentrations of TGF–β. (3) α is determined
by fitting model simulations, with the parameters Dp, β, and Dm as above, to the
total population data (see Figure 4 B).
It is possible that different values for Dm and α give rise to very similar total pop-
ulation growth curves. We determine ratios of Dm and α for treatment and control
cases that simulate our experimental growth data (Figure 4 B). Our determination
of Dm (corresponding to motility) and of α (corresponding to proliferation) reveals
that TGF–β roughly doubles the value of Dm and halves the value of α. The total
population growth data of the cell cultures alone (without any further information)
are insufficient to quantify these two separate effects of TGF–β. We have used in
addition the motility experiment data to distinguish the two effects.
We have developed a general spatial model of proliferating cell cultures in vitro,
which allows quantification of the properties of proliferative capacity, cell mobility,
and clustering as the population attains confluence. The novelty of our interpre-
tation of the Fisher–Kolmogorov equation is that cells begin as isolated geometric
regions corresponding to seeding. As they proliferate and migrate these regions ex-
pand as controlled by the diffusion parameters and proliferation parameter. When
the density is identically β−1 (whose value is readily correlated to the average area
occupied by an individual cell), the region occupied is completely populated. When
the density is < β−1 in a region, then the integral of the density over this region is
the expected value of the number of cells in the region. Our focus here is on quan-
tification of the effects of TGF–β on motility and proliferation for in vitro cancer
cell cultures, but our model allows investigation of similar phenomena for many cell
types, both prokaryotic and eukaryotic. Extensions and modifications of our model
could incorporate different cell proliferation dynamics, multiple cell types and cell
interactions (for example endothelial cells, hematopoietic cells, and immune cells),
in both in vitro and in vivo settings. In the future we plan to add more components
that naturally exist in the tumour microenvironment to the model, including stro-
mal fibroblasts, immune cells and vascular endothelial cells, which are all affected
by TGF–β. In addition, many tumours carry key mutations on oncogenes or tu-
mour suppressor genes, which may affect their responses to TGF–β. For example,
cancer cells can become unresponsive to the anti–proliferative function of TGF–
β, while remaining sensitive to TGF–β–induced motility. Inactivating mutations
of TGF–β receptors are frequently found in pancreatic, biliary and colon cancers
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[14, 21, 40]. Usually, only a subset of cancer cells in a tumour harbour these muta-
tions and these cells live together and communicate with other wild–type epithelial
cells, fibroblasts and endothelial cells. It will be important to further investigate
with the proper assistance from a mathematical model how these cancers are af-
fected by TGF–β. The dual function of TGF–β as both a tumour suppressor and
promoting factor is reflected by its individual effects on inhibiting cell proliferation
and stimulating cell motility. Primary tumour growth by active cell proliferation
results in the increase of tumour size. However, during cancer progression, dis-
semination of tumour cells from primary site into circulation and the subsequent
invasion of other organs, in which cell motility plays a critical role, usually deter-
mine the grade of malignancy and the outcome of cancer treatment. Therefore,
despite the fact that TGF–β has been considered a promising therapeutic target
to treat certain types of cancer, the uncertainty of the overall effects of TGF–β
intervention due to the potential risk of derepressed tumour cell proliferation has
been an unsolved critical issue. This requires further in–depth understanding of the
different aspects of TGF–β action through highly quantitative approaches such as
mathematical modeling. Our model described here is the first step of encapsulat-
ing the multiple functions of a signalling molecule and potential therapeutic target
such as TGF–β into a computational model. By introducing the modeling method
to the cancer biology of TGF–β, questions that have been raised for years will have
the chance to be answered from a novel angle. These interesting topics include: (1)
When is the critical time of TGF–β being switched from a tumour suppressor to
a promoter? (2) When is the most efficient time to apply anti–TGF–β therapy
during cancer progression? (3) Will therapeutic inhibition of TGF–β at pre–cancer
lesions or at early stages of the disease trigger primary tumour growth as a result
of derepression of cell proliferation? Besides the complexity of TGF–β signalling,
cancer cells can respond differently to TGF–β. For example, several oncogenes in-
cluding HER2 are known to synergize with TGF–β to function on cell motility and
survival. Some cancers do not respond to the anti–proliferative effect of TGF–β
but still respond to its stimulatory effect on motility. The mathematical model
will therefore provide a unique way to simulate how TGF–β functions differently
in cancer cell populations with different characteristics, and the effect of TGF–β
therapeutic inhibition on a tumour consisting of heterogeneous cell populations.
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Table 1. The percentage of mobile cells in the single cell experiments as function of TGF–β concentration
c (ngml−1) motility (%)
0 33
0.5 45
1 49
2 51
5 56
Table 2. The parameter values used in the simulations shown in figure 4 B
TGF–β Dm (µm2h−1) Dp (µm2h−1) α (h−1)
− 5 0.1 0.07
+ 10 0.1 0.04
A B
Figure 1. A Selected r2 vs. k curves for untreated cells. Position measurements of cells were taken and
the mean–squared displacement was calculated according to equation (4). Out of 20 available curves six
showed a roughly linear dependence of r2(k). B Selected r2 vs. k curves for cells treated with TGF–β.
The time unit is 5 min for both panels, while the mean–squared displacement is in µm2.
Figure 2. Random motility of cell clusters in the absence and presence of TGF–β. The movies are
represented by 5 different frames at the indicated times. The bar equals 10µm.
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Figure 3. A Coverage radii for cell clusters in absence (blue) and presence (red) of TGF–β. The fact
that all vectors point into the first quadrant is due to a minor technicality. B The variation of the
squared radii is computed according to equation (6) for six different movies. The control cases are shown
in blue, the treatment cases in red. These figures are representative for three independent realisations of
the experiment.
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Figure 4. A Simulation of untreated cells growing according to the modified Fisher–Kolmogorov
equation (3) in a square subfield of the culture dish with side 300µm. Periodic boundary conditions are
assumed to account for a balance of cells entering and exiting the subfield. Initially, 75 cells were seeded
randomly across the domain. Snapshots are taken at t = 72h (initial datum, upper left) and t = 92, 112h
and t = 132h. The parameters are Dm = 5µm2h−1, Dp = 0.1µm2h−1 and α = 0.07h−1. B Normalised
growth curves (solid curves, simulation) and experimental measurements (discrete symbols) over a time
course of 5 days. Shown are the untreated cells (control, +) and cells treated with TGF–β (◦).
